How can a Chinese dual antibody become a pivot point
Time：
2026-06-26 18:24
Author：
xieyijun
CPIC 2026 | Protheragen Session: Global Biomedical Cross-Border Transactions
Jointly explore sustainable and high-quality ways to expand globally.
Time：
2026-06-25 18:16
Author：
xieyijun
Entering the 3.0 era of self exemption, Chinese pharmaceutical companies sit at the table
AbbVie invests $10.9 billion in ultra long term investments
Time：
2026-06-25 18:12
Author：
xieyijun
The 'Chinese genes' of the $2 trillion era
Time：
2026-06-25 08:08
Author：
xieyijun
2026: Recovery, Breakthrough, and Gaming of Universal CAR-T
Technical value is repriced by clinical data
Time：
2026-06-24 08:12
Author：
xieyijun
When American investors defend Chinese new drugs
Time：
2026-06-21 19:28
Author：
xieyijun
Synthesize deadly 'new aristocrats' soaring wildly
Time：
2026-06-20 17:06
Author：
xieyijun
Recommended content
mRNA tumor vaccine "seller", entering a golden age
When a Biotech company that has been acquired achieves rare growth
AI、 Cold bench and puzzle, when will 'one person, one seedling' come to an end?
This road is long, but the threshold has already been crossed.
The "economic accounts" of immunology business development are being rewritten
After rejecting a $30 billion acquisition offer, a biotech company has emerged as a giant
determination for independence
联系我们
同写意
写意宣发
同写意Biotech
同写意微服务